By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
INTRODUCTION
Cross-border shipping for clinical trials is frequently necessary. Managing these shipments can take a lot of time for clinical trial coordinators, investigators, and other medical experts when combined with the difficulties of many international regulatory authorities.
The precise, compliant fulfilment of a clinical trial protocol with ongoing real-time visibility depends critically on the strategic management of logistics and supply chain. A favourable medical outcome may be increased by significant investments in research and development (R&D) and by having a sufficient supply and logistics infrastructure.
GLOBAL CLINICAL TRIAL LOGISTICS MARKET SIZE AND FORECAST
The Global Clinical Trial Logistics market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
MARKET ANALYSIS
At different phases of clinical distribution, clinical trial providers work with a large number of third-party vendors and technicians to ensure that the study pharmaceuticals given are of a sufficient quantity and quality. This management, in terms of pharmaceutical supply, offers complete tracking from manufacturing to dispensing and disposal, lowering hazards like product expiration or depletion.
Major market drivers include the rise in clinical trials and regulatory harmonisation, expanding R&D expenditures by pharmaceutical and biotechnology businesses, and technical advancements in the supply chain.
Clinical trial costs are rising, which has led to a rise in the outsourcing of these services.Clinical trial sponsors had significant difficulties during the COVID-19 epidemic, and the industry was forced to deal with logistical concerns. The conventional supply chain has been greatly changed by the remote trial technique’s quick and widespread adoption.
The numerous logistical issues posed by remote research were addressed via direct-to-patient technologies. Sponsors may reach a large audience more easily with decentralised trials.
Despite the fact that the pandemic has increased the acceptance of these trials, there will still be a sizable need for them even after COVID-19 is eliminated. The market was badly impacted by COVID-19 as a result of supply chain delays and the government’s decision to curtail the number of commercial aeroplanes in order to stop the virus’s spread.
COMPANY PROFILE
THIS REPORT WILL ANSWER FOLLOWING QUESTIONS
